![](images/null.gif) |
![](images/null.gif) |
![](images/null.gif) |
|
SAFETY AND EFFICACY OF THE COMBINATION DACLATASVIR-SOFOSBUVIR IN HCV GENOTYPE 1-MONO-INFECTED PATIENTS FROM THE FRENCH OBSERVATIONAL COHORT ANRS CO22 HEPATHER
|
|
|
from Jules: by looking at Base Line characteristics in tables below: 18% had diabetes, 78% had cirrhosis, 31% hypertension, 9% decompensated cirrhosis, 50% Gt1a/44% Gt1b, 34% wit platelet counts <100,000, 10% with ALT>5x ULN..... with 12 or 24 weeks DCV/Sof/Rbv 97-100% achieved SVR.
Reported by Jules Levin
EASL 2015 April 22-26 Vienna Austria
Stanislas POL, Marc BOURLIERE, Sandy LUCIER, Victor DE LEDINGHEN, Fabien ZOULIM, Celine DORIVAL-MOULY, Sophie METIVIER, Dominique LARREY, Albert TRAN, Christophe HEZODE, Jean-Pierre BRONOWICKI, Didier SAMUEL, Patrick MARCELLIN, Jean-Pierre ZARSKI, Anne MINELLO, Laurent ALRIC, Jean-Claude TRINCHET, Pierre NAHON, Dominique GUYADER, Olivier CHAZOUILLERES, Ghassan RIACHI, Veronique LOUSTAUD-RATTI, Xavier CAUSSE, Philippe MATHURIN, Isabelle HUBERT-FOUCHARD, Isabelle ROSA, Yves BENHAMOU, Jerome GOURNAY, Jean-Jacques RAABE, François RAFFI, Ventzislava PETROV-SANCHEZ, Alpha DIALLO, Helène FONTAINE, Fabrice CARRAT on the behalf of the ANRS/AFEF HEPATHER study group
![EASL1.gif](../images/042715/042715-5/EASL1.gif)
![EASL2.gif](../images/042715/042715-5/EASL2.gif)
![EASL3.gif](../images/042715/042715-5/EASL3.gif)
![EASL4.gif](../images/042715/042715-5/EASL4.gif)
![EASL5.gif](../images/042715/042715-5/EASL5.gif)
![EASL6.gif](../images/042715/042715-5/EASL6.gif)
![EASL7.gif](../images/042715/042715-5/EASL7.gif)
![EASL8.gif](../images/042715/042715-5/EASL8.gif)
![EASL9.gif](../images/042715/042715-5/EASL9.gif)
![EASL10.gif](../images/042715/042715-5/EASL10.gif)
|
|
|
![](images/null.gif) |
![](images/null.gif) |
|
|